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CEL-1000 (DGQEEKAGVVSTGLIGGG) is a novel potential preventative and therapeutic agent. We report
that CEL-1000 confers a high degree of protection against Plasmodium sporozoite challenge in a murine model
of malaria, as shown by the total absence of blood stage infection following challenge with 100 sporozoites
(100% protection) and by a substantial reduction (400-fold) of liver stage parasite RNA following challenge
with 50,000 sporozoites. CEL-1000 protection was demonstrated in A/J (H-2a) and C3H/HeJ (H-2k) mice but
not in BALB/c (H-2d) or CAF1 (A/J  BALB/c F1 hybrid) mice. In CEL-1000-treated and protected mice, high
levels of gamma interferon (IFN-) in serum and elevated frequencies of hepatic and splenic CD4 IFN--
positive T cells were detected 24 h after administration of an additional dose of CEL-1000. Treatment of A/J
mice that received CEL-1000 with antibodies against IFN- just prior to challenge abolished the protection,
and a similar treatment with antibodies against CD4 T cells partially reduced the level of protection, while
treatment with control antibodies or antibodies specific for interleukin-12 (IL-12), CD8 T cells, or NK cells
had no effect. Our data establish that the protection induced by CEL-1000 is dependent on IFN- and is
partially dependent on CD4 T cells but is independent of CD8 T cells, NK cells, and IL-12 at the effector
phase and does not induce a detectable antibody response.
Malaria remains a major cause of mortality and morbidity in
tropical and subtropical areas of the world, with approximately
300 million people considered at risk of infection. Although
several clinical malaria vaccines have been developed and are
being evaluated for their protective efficacies (for a review, see
reference 19), prophylaxis and treatment with antimalarial
drugs remain the only options for effective malaria control. In
recent years, drug-resistant parasites have emerged and are
now widespread, presenting serious problems for malaria con-
trol. Therefore, new and effective antimalarial interventions,
both drugs and vaccines, are needed. It was previously dem-
onstrated (3) that immunization with linear synthetic peptides
containing B- and T-cell epitopes derived from the Plasmo-
dium yoelii 17-kDa hepatocyte-erythrocyte protein (PyHEP17)
protected A/J and CD1 mice but not BALB/c or C57BL/6 mice
against sporozoite challenge, and this protection was depen-
dent on CD4 T cells and gamma interferon (IFN-) but not
on CD8 T cells. The protected mice displayed a Th1-type
antibody profile (immunoglobulin G2a [IgG2a]), while the
nonprotected mice displayed a predominant Th2-type antibody
profile (IgG1).
The ligand epitope antigen presentation system technology
came out of our efforts to direct the immune response toward
a Th1 or Th2 orientation for a synthetic peptide vaccine. Im-
munization of mice with a Mycobacterium antigen conjugated
to various T-cell binding ligands (TCBLs) induced either Th1-
or Th2-type antibody responses to the native epitope of the
38-kDa protein of Mycobacterium tuberculosis, depending upon
the TCBL used (26). The TCBL peptides have been shown to
enhance the immunogenicities of antigenic epitopes, activate T
cells, and direct the immune response to either a Th1-type
antibody by use of a peptide (referred to as peptide J) from -2
microglobulin or a Th2-type antibody by use of a peptide
(referred to as peptide G) from the  chain of the major
histocompatibility complex (MHC) class II (MHC-II) mole-
cule and the immunogens (20, 26, 27). In other studies with the
herpes simplex virus (HSV) model, heteroconjugate vaccines
containing a T-cell epitope from HSV type 1 (HSV-1) glyco-
protein D and peptide J as the TCBLs have been shown to
elicit Th1-type responses and protection against HSV-1 chal-
lenge (5, 20). More recently, using a modified G called derG
(the peptide that has now been renamed CEL-1000), we ob-
served that, in contrast to the TCBL peptide G, CEL-1000
induced a human immunodeficiency virus Gag protein Th1-
type antibody profile (IgG2a), with very low levels of antibod-
ies to peptide J or derG (D. H. Zimmerman et al., unpublished
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observations). Since peptide J and CEL-1000 conjugated to
immunogenic peptides have been shown to induce specific
Th1-type antibody responses and protection in other disease
models, the ability of peptide J or CEL-1000 peptide to en-
hance PyHEP17-mediated protection was evaluated.
Here we report that treatment of A/J mice with a suboptimal
dose (5 g) of conjugated CEL-1000–HEP17 peptide in Titer-
Max adjuvant induced higher, borderline significantly different
levels of protection against challenge with 100 P. yoelii sporo-
zoites than treatment with HEP17 alone (P  0.0698). Unex-
pectedly, we observed that treatment with CEL-1000, a TCBL
control peptide, protected 100% of the mice against parasite
challenge in the absence of malaria parasite antigen; and this
protection was significantly higher than that induced by the
HEP17 peptide (P  0.0031). In subsequent experiments we
observed that treatment with only 5 g of CEL-1000 protected
100% of A/J mice against challenge with 5,000 sporozoites, a
dose that was 50-fold higher than the minimum infectivity dose
(100 sporozoites); we also observed that treatment with CEL-
1000 protected C3H/HeJ mice against sporozoite challenge.
The finding that CEL-1000 protected A/J mice in the absence
of malaria parasite antigen is astonishing. It is not clear why
this peptide is protective. To our knowledge, there is no report
indicating that CEL-1000 contains a sequence homologous to
those of any malaria parasite antigens. This is the first report
indicating that a peptide derived from the  chain of human
MHC-II is protective against malaria. This finding prompts us
to further evaluate the protective effect of CEL-1000 in rela-
tion to the potency, duration of protection, stage specificity of
protection, and possible mechanisms associated with this pro-
tection.
MATERIALS AND METHODS
Mice. Four- to 5-week-old inbred female A/J (H-2a), BALB/c (H-2d), CAF1
(F1 hybrid between A/J and BALB/c), and C3H/HeJ (H-2k) mice (The Jackson
Laboratory, Bar Harbor, Maine) and outbred CD1 mice (Charles River Labo-
ratory, Wilmington, Mass.) were used. The experiments reported herein were
conducted according to the principles set forth in the Guide for the Care and Use
of Laboratory Animals (15). All animal studies were performed with the approval
of the Navy Medical Research Command Institutional Animal Care and Use
Committee.
Parasites. P. yoelii (nonlethal strain 17XNL, clone 1.1) and P. berghei (lethal
strain ANKA) were maintained by alternating passage of the parasites in Anoph-
eles stephensi mosquitoes and outbred CD1 mice. Sporozoites isolated from the
salivary glands of infected mosquitoes were used in the challenge studies to
determine the blood stage parasitemia. Sporozoites isolated from the thoraxes of
infected mosquitoes by the discontinuous gradient technique (17) were used in
the challenge studies to determine the liver stage parasite burden.
Peptides. The five peptides used in this study included HEP17, a 25-amino-
acid peptide (SFPMNEESPLGFSPEEMEAVASKFR) containing protective B
and T epitopes from the P. yoelii hepatocyte-erythrocyte 17-kDa protein (3); J, a
16-amino-acid TCBL peptide (DLLKNGERIEKVEGGG) from human MHC-I
-2 microglobulin (5, 18, 20, 26, 27); CEL-1000, an 18-amino-acid TCBL peptide
(DGQEEKAGVVSTGLIGGG) from the second domain of the  chain of the
human MHC-II molecule (2, 5, 9, 20, 26, 27); J-HEP17, a peptide containing
amino acid sequences from the J and HEP17 peptides (DLLKNGERIEKVEG
GG-SFPMNEESPLGFSPEEMEAVASKFR); and CEL-1000–HEP17, a pep-
tide containing amino acid sequences from the CEL-1000 and HEP17 peptides
(DGQEEKAGVVSTGLIGGG-SFPMNEESPLGFSPEEMEAVASKFR). All
peptides were synthesized by Biosource International (Hopkinville, Mass.) or
UCB (Atlanta, Ga.) by the 9-fluorenylmethoxy carbonyl method and were puri-
fied by high-pressure liquid chromatography (95% purity). These peptides
were used for immunization or treatment studies. The HEP17 peptide was also
used in an enzyme-linked immunosorbent assay (ELISA) for analysis of serum
HEP17-specific antibodies.
Antibodies. The antibodies used for the in vivo depletion study included
purified rat Ig control antibodies (Rockland Company, Gilbertsville, Pa.); anti-
CD4 monoclonal antibody (MAb) GK1.5, rat IgG2a (from a hybridoma cell
line; catalog no. TIB207; American Type Culture Collection, Manassas, Va.);
anti-CD8 MAb 2.43, mouse IgG2a (from a hybridoma cell line; catalog no.
TIB210; American Type Culture Collection); anti-IFN-MAb XMG-6, rat IgG1
(from a hybridoma cell line; provided by F. Finkelman, University of Cincinnati
Medical Center, Cincinnati, Ohio); anti-interleukin-12 (anti-IL-12) MAb C17.8,
rat IgG2a (from a hybridoma cell line; provided by M. Wysocka and G. Trinch-
ieri, Wistar Institute, Philadelphia, Pa.); and anti-NK cell antibody, rabbit anti-
N-asialo GM1 sera (Wako Bioproducts, Richmond, Va.). Ascitic fluids were
produced by Harlan Bioproducts for Science (Indianapolis, Ind.), using hybrid-
oma cell lines secreting the MAbs listed above. The MAbs were purified by 50%
ammonium sulfate precipitation, and the final antibody concentrations were
determined by measurement of the optical density.
Protection of A/J mice immunized with HEP17 peptide conjugated to J or
CEL-1000 peptide. A study was designed to determine the adjuvant effect of J or
CEL-1000 on the enhancement of protective immune responses of the P. yoelii
peptide (HEP17) in a murine model of malaria. Briefly, groups of 10 A/J mice
were subcutaneously immunized at the base of the tail, two times at 3-week
intervals, with 5 or 25 g of peptides in the presence of TiterMax adjuvant.
TiterMax adjuvant-immunized mice and malaria-naïve mice served as adjuvant
controls and infectivity controls, respectively. At 10 days after the second immu-
nization, sera were collected from all mice for HEP17-specific antibody analysis.
At 2 weeks after the last immunization, all mice were challenged by intravenous
injection in the tail vein of 100 infectious P. yoelii sporozoites (the minimum
infectivity dose) suspended in 200 l of medium 199 containing 2% normal
mouse serum. Parasitemia (blood stage infection) levels were determined by
microscopic examination of 200 oil-immersion fields of Giemsa-stained thin
smears of blood obtained from mice at 7 and 14 days postchallenge. Mice with
negative blood smears through 14 days postchallenge were considered protected.
Malaria parasite-specific antibody analysis. Pooled sera obtained 10 days
after the second immunization from mice immunized with J-HEP17, CEL-1000–
HEP17, and HEP17 were analyzed by ELISA for HEP17-specific antibody levels,
as described previously (3), by using 1 g of the HEP17 peptide per ml as the test
antigen and the J or CEL-1000 peptide as the control antigen.
ELISA analysis of serum for IFN-. Mice that received two immunizations of
conjugated or unconjugated peptide and that were protected against sporozoite
challenged were boosted again at 4 weeks after the second immunization with the
same dose of peptide used in the earlier immunizations. Twenty-four hours later
these mice were exsanguinated. Serum collected from the mice in each group
were pooled and analyzed in duplicate for circulating IFN- by a standard
ELISA with cytokine ELISA kits (Endogen, Woburn, Mass.) and by the protocol
described by the manufacturer. The IFN- concentration was calculated by
interpolation from a standard curve based on recombinant IFN- dilutions run
in parallel in the same plate and read on an automated micro-ELISA reader
(MR5000; Dynatech) equipped with the manufacturer’s software.
Intracellular cytokine analysis. Spleen and liver cells were obtained from
some of the protected mice immunized with the conjugated and the unconju-
gated peptides (n  3 mice per group) and that were boosted again at 4 weeks
after the second immunization. Mice immunized with TiterMax adjuvant alone
served as negative controls. At 24 h after the last immunization, the livers and
spleens were removed from the mice for use in this assay. These organs were
homogenized in phosphate-buffered saline (PBS) in a homogenizer (Tissue
Sieve; Bellco Glass Inc., Vineland, N.J.), and 5  105 spleen or liver cells from
the tested or control mice were aliquoted into 96-well U-bottom plates and
washed with cold PBS. Cells were stained with labeled antibodies to the surfaces
of CD8 cells (fluorescein isothiocyanate [FITC]), CD4 cells (phycoerythrin
[PE]), or NK cells (allophycocyanin; Pharmingen, San Diego, Calif.) for 20 min
on ice. The cells were washed twice and permeabilized in 100 l of Cytofix/
Cytoperm buffer (Pharmingen) and then stained intracellularly for cytokines with
PE or FITC antibodies conjugated to IL-2, IL-4, IL-5, IL-10, IFN-, and tumor
necrosis factor alpha (Pharmingen), according to the directions of the manufac-
turer. For each sample, 80,000 to 200,000 events collected with a four-color
FACSCALIBUR instrument (Becton Dickinson, San Jose, Calif.) were analyzed
with Cellquest software (Becton Dickinson). All assays were performed in 96-
well plates.
Protection of mice treated with CEL-1000 peptide in TiterMax adjuvant. To
determine the protective efficacy of CEL-1000, groups of 10 A/J mice were
subcutaneously injected once or twice with 1.25 to 25 g of CEL-1000 in Titer-
Max adjuvant. Mice that received adjuvant alone or malaria-naïve mice served as
negative controls. At 2 weeks after administration of the last dose of CEL-1000,
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the mice were challenged with 100 P. yoelii sporozoites and parasitemia levels
were determined at 7 and 14 days postchallenge.
To determine the kinetics and maintenance of protection, the mice were
challenged with 100 P. yoelii sporozoites at 1, 2, or 4 weeks after the adminis-
tration of one or two doses of 5 g of CEL-1000 in TiterMax adjuvant.
To determine the protective effect of CEL-1000 in different mouse strains,
groups of 10 mice of different strains (A/J, BALB/c, CAF1, and C3H/HeJ) were
subcutaneously injected twice at 3-week intervals with 25 g of CEL-1000 in
TiterMax adjuvant and were challenged 2 weeks later with 100 P. yoelii sporo-
zoites. Mice that received TiterMax adjuvant alone and naïve mice served as
negative controls.
In some experiments mice treated twice at 3-week intervals with 5 g of
CEL-1000 were challenged with 100 P. yoelii-infected erythrocytes (RBCs) to
determine the stage specificity of protection or with 100 P. berghei sporozoites to
determine the species specificity of protection. Since our previous infection
studies indicated that malaria-naïve mice that received an intravenous injection
of 100 P. yoelii-infected RBCs or 100 P. berghei sporozoites developed para-
sitemia within 2 to 10 days postinjection, we determined daily the parasitemia
levels in mice treated with CEL-1000 and challenged with infected RBCs or mice
treated with CEL-1000 and challenged with P. berghei sporozoites, beginning on
day 2 and continuing to day 10 postchallenge. Mice that were blood smear
negative through 14 days after P. yoelii sporozoite challenge or mice that were
blood smear negative through 10 days after P. yoelii-infected RBC or P. berghei
sporozoite challenge were considered protected.
Evaluation of liver stage parasite burden. (i) Preparation of liver RNA for
real-time quantitative PCR (RTQ-PCR). For the evaluation of the liver stage
parasite burden, liver cells isolated from mice that received two injections of 5 g
of CEL-1000 in TiterMax adjuvant were used for TaqMan analysis (25). Livers
harvested from mice at 42 h after challenge with 50,000 sporozoites were placed
in 15 ml of Trizol reagents (Life Technologies, Gaithersburg, Md.) and homog-
enized for 90 s at full power with a TH polytron homogenizer (Omni Interna-
tional, Warrenton, Va.). Liver homogenates were aliquoted and stored at 80°C
until further RNA isolation could be performed. Total RNA was purified by the
standard protocol specified for Trizol by the manufacturer (Invitrogen Life
Technologies, Carlsbad, Calif.). The purified total RNA was resuspended in 200
l of 1 lysis buffer (catalog no. 4305895; Applied Biosystems, Foster City,
Calif.) and loaded into a 96-well plate (Invitrogen). Total RNA was further
purified with an ABI Prism 6700 automated nucleic acid workstation equipped
with an RNA purification tray plate (part no. 4305673; Applied Biosystems. RNA
samples were eluted with 200 l of nucleic acid purification elution solution
(catalog no. 4305893; Applied Biosystems).
(ii) Liver parasite burden assay (RTQ-PCR). The master mixture for RTQ-
PCR that was prepared contained 2 One-Step RT-PCR master mixture (Ap-
plied Biosystems), 100 nM VIC-labeled rodent GAPDH-specific probe (Applied
Biosystems, Foster City, Calif.), 200 nM 6-carboxyfluorescein-labeled P. yoelii
18S rRNA-specific probe, 80 nM rodent GAPDH-specific forward primer (Ap-
plied Biosystems), 20 nM rodent GAPDH-specific reverse primer (Applied Bio-
systems), and 300 nM each P. yoelii 18S rRNA-specific forward primer (primer
Py685f) and reverse primer (primer Py782R). The ABI Prism 6700 automated
nucleic acid workstation (Applied Biosystems) was programmed to dispense 18
l of each purified RNA sample into 22 l of the complete master mixture, and
the plates were sealed with optical heat seal covers (part no. 43D7726; Applied
Biosystems). Each sample and control was tested in triplicate. Real-time fluo-
rescence detection of the PCR products was performed with an ABI 7700
detector (Applied Biosystems) by using the following thermocycling conditions:
42°C for 30 min to synthesize cDNA, 95°C for 10 min to inactivate the reverse
transcriptase and activate the DNA polymerase, and 50 cycles at 95°C for 15 s
and 60°C for 1 min. Standard curves were generated for both the rodent GAPDH
and P. yoelii 18S RNA, and the quantitative parasite burden data were calculated
as outlined previously (25). The liver stage parasite burdens are expressed as the
mean 	 standard error of the mean ratio between P. yoelii 18S RNA plasmid
equivalents and mouse GAPDH plasmid equivalents obtained from the tested
and control mice (n  3).
Mechanism of CEL-1000-induced protection. To identify the specific cell sub-
sets and cytokines involved in CEL-1000-induced protection, groups of 10 A/J
mice were treated twice at 3-week intervals with 5 g of CEL-1000 in TiterMax
adjuvant. These mice were then treated with purified rat Ig control antibodies
(rat Igs) or with specific antibodies (anti-CD4 T cells, MAb GK1.5; anti-CD8
T cells, MAb 2.43; anti-IFN-, MAb XMG 6; anti-NK cells, anti-asialo GM1), as
described previously (3). For anti-IL-12 treatment, mice received two intraperi-
toneal injections of 1 mg of MAb C17.8 (anti-IL-12) in 0.5 ml of PBS 12 h before
and 3 h after sporozoite challenge. All mice were challenged 14 days after
administration of the second dose of CEL-1000, and the level of parasitemia was
determined as described above. To confirm the efficacy of cell subset depletion,
at 1 day before sporozoite challenge, blood samples were collected from each
group of mice and analyzed by FACScan analysis (Becton Dickinson) for deter-
mination of the percentage of each cell type. The depletion efficiencies were
97% for CD4, CD8, and NK cells.
Statistical analysis. The differences in the levels of protection among groups
was analyzed by the chi-square test (uncorrected) or Fisher’s exact test (two
tailed) if the expected cell value was less than 5 (Epi Info Version 6.04b; Centers
for Disease Control and Prevention, Atlanta, Ga.). The differences in the levels
of parasite RNA among groups were analyzed by Student’s unpaired t test of
log-transformed data. The differences in the frequencies of cell subsets produc-
ing IFN- among the groups were analyzed by Student’s unpaired t test.
RESULTS
Protection induced by HEP17 peptide conjugated to J or
CEL-1000 peptide. Initially, we evaluated the effect of conju-
gation of either the J or CEL-1000 peptide to a PyHEP17
peptide (representing defined B- and T-cell epitopes) on pro-
tection against P. yoelii sporozoite challenge. The results shown
in Fig. 1 indicate that A/J mice (n  10 mice per group) that
received a high dose (25 g) of J-HEP17, CEL-1000–HEP17,
or unconjugated HEP17 in TiterMax adjuvant had similar lev-
els of protection (90 to 100%). Mice that received a suboptimal
dose (5 g) of CEL-1000–HEP17 had a significantly higher
level of protection than mice that received J-HEP17 (P 
0.0017) but not a significantly higher level of protection than
mice that received HEP17 alone (P  0.0697). Mice immu-
nized with J-HEP17, CEL-1000–HEP17, and HEP17 devel-
oped HEP17-specific antibodies; but none of the mice immu-
nized with J or CEL-1000 developed anti-HEP17, anti-J, or
anti-CEL-1000 antibodies (data not shown). Unexpectedly, we
observed 100% protection in mice that received 5 or 25 g of
CEL-1000 without malaria parasite antigen. The finding that
CEL-1000 is protective against sporozoite-induced malaria
prompted us to further evaluate the prophylactic effect of this
FIG. 1. Protective efficacies of peptides against P. yoelii infection in
A/J mice immunized with conjugated peptides (J-HEP17 and CEL-
1000–HEP17) or unconjugated peptides (HEP17, J, and CEL-1000).
Mice (n 10 mice per group) were immunized with 5 or 25 g of each
peptide in TiterMax adjuvant twice at 3-week intervals and were chal-
lenged 2 weeks later with 100 sporozoites. The levels of parasitemia
were then determined as described in Materials and Methods. Mice
that received TiterMax adjuvant alone and malaria-naïve mice served
as negative controls (cont.). Protection was defined as negative blood
smear results through 14 days postchallenge.
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compound in the murine model of malaria in relation to the
potency, duration of protection, and the species and stage
specificities of protection and the possible mechanisms associ-
ated with this protection.
Evaluation of potency of CEL-1000. To evaluate the potency
of CEL-1000, A/J mice (n  10/group) that received two in-
jections of 1.25 to 5 g of CEL-1000 in TiterMax adjuvant were
challenged with 100 to 5,000 sporozoites, followed by determi-
nation of the parasitemia level. The results in Table 1 indicate
that two injections of as little as 1.25 g of CEL-1000 in
TiterMax adjuvant protected 60% of the mice against chal-
lenge with 100 sporozoites (the minimum infectivity dose), and
two injections of 5 g of CEL-1000 protected 100% of the mice
against challenge with up to 5,000 sporozoites. These data
demonstrate that CEL-1000 is a very potent agent for prophy-
laxis against P. yoelii sporozoite-induced infection.
Serum cytokine levels and frequencies of cell subsets in
peptide-immunized and protected mice. Since previous studies
(3) established that PyHEP17 peptide-induced protection is
dependent on CD4 T cells and IFN-, we investigated
whether the protection induced by these conjugated and un-
conjugated peptides was mediated by similar immune mecha-
nisms. Accordingly, we measured serum IFN- levels in the
immunized and protected mice by ELISA and the frequencies
of CD4 IFN--positive (IFN-) T cells in livers and spleens
by staining for intracellular cytokines. The immunized and
protected mice were boosted again with the same dose of
peptide used in the previous immunization, and sera collected
24 h later from each group of mice were pooled and analyzed
by ELISA, as described in Materials and Methods. The results
in Fig. 2 show that sera pooled from CEL-1000–HEP17-im-
munized and protected mice (5-g dose, n  5; 25-g dose, n
 9), HEP17-immunized and protected mice (5-g dose, n 
3; 25-g dose, n  10), and CEL-1000-immunized and pro-
tected mice (5 or 25 g dose, n  10) had different serum
IFN- levels, with the highest levels detected in CEL-1000-
immunized and protected mice. Intracellular staining of liver
cells isolated from immunized and protected mice (n  3 mice
per group) 24 h after the booster injection showed higher
frequencies of CD4 IFN- T cells in the immunized and
protected mice that received the high dose of CEL-1000–
HEP17 or the HEP17 peptide and the mice that received 5 or
25 g of CEL-1000 than the frequencies in mice that received
TiterMax adjuvant (n  2 mice per group), with the highest
frequency detected in CEL-1000-immunized and protected
mice (Fig. 3). Because of the small sample sizes (n 3) and the
low frequencies of CD4 IFN- cells, the only comparison
that can be made is between the TiterMax adjuvant-treated
control group and the CEL-1000-treated group (P  0.0719,
Student’s t test, two tailed). Slight increases in the frequencies
of splenic CD4 IFN- T cells and CD4 IFN- T cells
were also observed (data not shown). These findings establish
that immunization of mice with CEL-1000 in TiterMax adju-
vant induces higher levels of serum IFN- and higher frequen-
cies of hepatic and splenic CD4 IFN- T cells, as well as
higher levels of protection, compared to those achieved by
immunization with conjugated CEL-1000–HEP17 or unconju-
gated HEP17 peptide. The data are consistent with the roles of
FIG. 2. Serum IFN- levels in immunized and protected mice. At 4
weeks after the second immunization, the immunized and protected
mice (5 g of CEL-1000–HEP17, n  8; 25 g of CEL-1000–HEP17,
n  9; 5 g of HEP17, n  3; 25 g of HEP17, n  10; 5 or 25 g of
CEL-1000, n  10 for each dose group) were boosted again with the
same dose of each peptide used in the previous immunization. Serum
samples were collected from the mice 24 h later. Sera from mice in
each group were pooled and analyzed by ELISA to determine IFN-
levels, as described in Materials and Methods.
TABLE 1. Potency of CE1-1000 in A/J micea
Expt no. and antigen dose (g) or
treatment
No. of sporozoites
used for challenge No. of mice protected/no. tested % Protection P value
b
Expt 1
1.25 100 6/10 60 0.0190763
2.5 100 8/10 80 0.0016537
5 100 10/10 100 0.0000523
TiterMax adjuvant (control) 10 1/10 10
Expt 2
5 100 10/10 100 0.0000077
5 1,000 10/10 100 0.0000077
5 5,000 10/10 100 0.0000077
TiterMax adjuvant (control) 100 0/10 0
a Mice were injected twice at 3-week intervals with various doses of CEL-1000 in TiterMax adjuvant and were challenged 2 weeks later with different numbers of
P. yoelii sporozoites, as indicated. Protection was defined as negative blood smear results through 14 days postchallenge.
b A P value 0.05 (chi-square test) compared to the result for the relevant control was considered significant.
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IFN- and CD4 IFN- T cells in CEL-1000-induced pro-
tection in the murine model of P. yoelii malaria.
Kinetics of induction and maintenance of CEL-1000-in-
duced protection. Since CEL-1000 was capable of protecting
mice against sporozoite challenge, we next evaluated the ki-
netics of induction and maintenance of protection in A/J mice.
Mice injected with one or two doses of 5 g of CEL-1000 (at
3-week intervals) were challenged with 100 P. yoelii sporozoites
at 1, 2, or 4 weeks after administration of the last dose of
CEL-1000. Mice treated with TiterMax adjuvant alone served
as controls. The results in Fig. 4 demonstrate that as early as 1
week after treatment, 40% of the mice that received a single
dose of CEL-1000 and 90% of the mice that received two doses
of CEL-1000 were protected. The level of protection increased
with time after CEL-1000 treatment (greater protection at
week 2 compared to that at week 1) and was maintained for at
least 4 weeks, with protection levels of 90 and 100% in mice
that received one and two doses of CEL-1000, respectively. A
small number (n  5) of protected and available mice were
rechallenged 4 months later after they were given an additional
booster injection, and 80% of these mice remained protected
(data not shown). These data suggest that the protection
against P. yoelii sporozoite challenge induced by CEL-1000 is
long lasting.
Protection against P. yoelii blood stage parasite challenge.
To evaluate the protective efficacy of CEL-1000 against blood
stage parasite challenge, mice that received two injections of 5
g of CEL-1000 in TiterMax adjuvant at 3-week intervals were
challenged at 2 weeks after the second injection with 100 P.
yoelii-infected RBCs. Mice that received TiterMax adjuvant
alone served as controls. None of the CEL-1000-treated mice
or TiterMax adjuvant-treated control mice were protected
against challenge with infected RBCs (data not shown). This is
in contrast to the results of sporozoite challenge, in which
protection was observed (Fig. 1 and 4). These results suggest
that the protection induced by CEL-1000 is not directed
against the blood stage parasites.
Protection against P. berghei sporozoite challenge. In the
experiment evaluating protection against P. berghei sporozoite
challenge, we treated groups of 10 A/J mice with two injections
of 5 g of CEL-1000 at 3-week intervals and challenged the
mice 2 weeks later with 100 P. berghei (lethal strain ANKA)
sporozoites. Only 2 of 10 (20%) of these mice were protected,
whereas none of the TiterMax adjuvant-treated control mice (0
of 10) or the infectivity control mice (0 of 10) were protected
(data not shown). These results indicate that with this admin-
istration regimen, CEL-1000 confers some degree of protec-
tion against challenge with sporozoites from a second species
of murine malaria parasites. The lower level of protection
against P. berghei sporozoite-induced malaria compared to that
against P. yoelii sporozoite-induced malaria may be because P.
berghei (lethal strain ANKA) is more virulent than P. yoelii
(nonlethal strain 17XNL). Normally, mice challenged with 100
P. berghei sporozoites exhibit blood stage parasitemia within 2
to 10 days and progress to death within 14 days, but in this
study parasitemia and not death was used as an end point of
the study (per Institutional Animal Care and Use Committee
approval). In contrast, mice challenged with 100 P. yoelii
17XNL sporozoites exhibited parasitemia later, within 5 to 14
days, and self-cured within 21 days.
Evaluation of liver stage parasite burden. To determine
whether the protection induced by CEL-1000 is directed
against the liver stage parasites, we injected A/J mice with two
doses of 5 g of CEL-1000 in TiterMax adjuvant and chal-
lenged the mice 2 weeks later with 50,000 P. yoelii sporozoites.
Mice that received TiterMax adjuvant alone or untreated mice
served as negative controls. The results in Fig. 5 demonstrate
that treatment of mice with CEL-1000 prior to challenge sig-
nificantly inhibited the liver stage parasite burden (P  0.01),
as determined by TaqMan RTQ-PCR analysis for parasite
RNA in the mouse livers. It should be noted that a greater than
400-fold reduction in the level of parasite RNA was observed
in mice treated with CEL-1000 before challenge compared to
FIG. 3. Frequencies of CD4 IFN- T cells in the livers of im-
munized and protected mice. At 4 weeks after the second immuniza-
tion, the immunized and protected mice (n  3 mice per group) were
boosted again with the same dose of immunogens used in the previous
immunization. Mice that received TiterMax adjuvant alone served as
controls (cont.). Liver cells harvested from individual mice 24 h later
were analyzed by intracellular cytokine staining, as described in Ma-
terials and Methods. The results are reported as the group mean 	
standard error of frequencies of CD4 IFN- T cells.
FIG. 4. Kinetics and duration of protection in A/J mice treated
with CEL-1000 peptide before challenge. Mice (n  10 mice per
group) that received one or two injections of 5 g of CEL-1000 in
TiterMax adjuvant at 3-week intervals and mice that received Titer-
Max adjuvant alone were challenged with 100 P. yoelii sporozoites at 1,
2, or 4 weeks after the last injection, followed by determination of
parasitemia levels, as described in Materials and Methods. Protection
was defined as negative blood smear results through 14 days postchal-
lenge.
VOL. 48, 2004 CEL-1000-INDUCED PROTECTION AGAINST MALARIA 2459
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
the levels in the TiterMax adjuvant-treated control mice or the
infectivity control mice. These data establish that the protec-
tion induced by CEL-1000 is directed against the liver stage of
the parasite life cycle.
Mechanisms of CEL-1000-induced protection. Next we at-
tempted to elucidate the immune mechanisms responsible for
CEL-1000-induced protection. Since both IFN- and CD4 T
cells have been implicated in malaria parasite peptide-induced
protection against sporozoite challenge (2, 21, 22), the mech-
anisms of CEL-1000-induced protection were evaluated by the
in vivo depletion of various cell subsets and cytokines from
CEL-1000-treated mice just prior to sporozoite challenge. The
results in Table 2 demonstrate that the mice that received
CEL-1000 in TiterMax adjuvant were completely protected
against parasite challenge, whereas the control mice treated
with TiterMax adjuvant alone were not protected. Treatment
of mice that received CEL-1000 with antibodies to IFN- prior
to challenge abolished the protection (P  0.0000077),
whereas 100% protection was achieved in mice that received
CEL-1000 and rat Ig control antibodies. Depletion of CD4 T
cells partially reduced (30%) the level of protection (P 
0.001). However, depletion of either CD8 T cells or NK cells
or treatment with antibodies to IL-12 did not alter the protec-
tion levels. These data suggest that the protection against P.
yoelii malaria delivered by CEL-1000 is dependent on IFN-
and is partially dependent on CD4 T cells but is independent
of CD8 T cells, NK cells, or IL-12 at the effector phase of the
responses, which is consistent with a Th1 response.
Protection in mice with different genetic backgrounds. Stud-
ies on the protective effect of CEL-1000 in mice with different
genetic backgrounds indicated that CEL-1000 had a protective
effect in A/J (H-2a) and C3H/HeJ (H-2k) mice, with A/J mice
protected at higher levels than C3H/HeJ mice. However, CEL-
1000 had no protective effect in BALB/c (H-2d) and CAF1
mice (CAF1 is an F1 hybrid of A/J and BALB/c mice) (Table
3). This genetic restriction of protection induced by CEL-1000
was similar to that induced by two malaria parasite peptides
that also protected A/J mice but not BALB/c mice against
sporozoite challenge (3, 23). Sera collected from A/J, BALB/c,
CAF1, and C3H/HeJ mice 10 days after the second injection of
25 g of CEL-1000 were analyzed by ELISA against CEL-1000
peptide and by immunofluorescence assay against mouse liver
cells and were negative by both assays, suggesting that treat-
ment of mice with CEL-1000 by this administration regimen
does not induce antibodies to MHC-II molecules (autoanti-
bodies).
DISCUSSION
CEL-1000 is an 18-amino-acid TCBL peptide containing
amino acid sequences derived from the 2 chain of human
MHC-II, except that the glutamine at the N terminus is re-
placed by glutamic acid. Initially, we evaluated the capacities of
two TCBL peptides (J and CEL-1000) to enhance the protec-
tion offered by a malaria parasite peptide (HEP17) in a murine
model of malaria. Two immunizations with a high dose (25 g)
of conjugated J-HEP17, conjugated CEL-1000–HEP17, or un-
conjugated HEP17 peptide in TiterMax adjuvant induced sim-
ilar levels of protection (90 to 100%). However, two immuni-
zations with a suboptimal dose (5 g) of CEL-1000–HEP17
FIG. 5. P. yoelii liver stage parasite burden in CEL-1000-treated
and challenged mice. Mice were treated with two injections of 5 g of
CEL-1000 in TiterMax adjuvant (n  5). Mice that received TiterMax
adjuvant alone (n  5) or malaria-naïve mice (n  3) served as
controls. At 2 weeks after the second injection, the mice were chal-
lenged with 50,000 sporozoites and their livers were isolated 42 h later
for analysis of the liver stage parasite burden, as described in Materials
and Methods. The liver stage parasite burden was expressed as the
group mean	 standard error of the mean of a ratio between amplified
parasite RNA plasmid equivalents and amplified mouse GAPDH plas-
mid equivalents.
TABLE 2. Depletion of IFN- eliminates protection from micea that received CEL-1000 in TiterMax adjuvant and depletion of CD4 T cells
partially reduces protection level
Treatment No. of mice protected/no. tested % Protection P valueb
CEL-1000, undepleted 10/10 100 0.0000077
Control TiterMax adjuvant 0/10 0
Anti-CD4 T cells 7/10 70 0.0010320
Anti-CD8 T cells 10/10 100
Anti-NK cells 10/10 100
Anti-IFN- 0/10 0 0.0000077
Anti-IL-12 0/10 100
Rat Ig control 10/10 100
a Mice that received CEL-1000 were treated with specific reagents (test and control antibodies), as described in Materials and Methods. Depletion efficiency was
determined by fluorescence-activated cell sorter analysis and was 97% for all cell types (CD4, CD8, and NK cells). Protection was defined as negative blood smear
results through 14 days postchallenge.
b A P value 0.05 (chi-square test) compared to the result for the relevant control was considered significant.
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induced higher levels of protection (80%) compared to those
achieved with two immunizations of HEP17 (30%), J-HEP17
peptide (10%), and the TiterMax adjuvant control (0%).
These results suggest that enhanced protection can be ob-
served with suboptimal doses of CEL-1000–HEP17, but this
level of protection was not significantly different from that
induced by HEP17 alone (P  0.0698). Unexpectedly, CEL-
1000 yielded 100% protection when it was administered with
TiterMax adjuvant without any malaria antigen. It is not known
why CEL-1000 is more protective in mice than CEL-1000–
HEP17. Two possible explanations based on our observations
are as follows. (i) Mice treated with CEL-1000 and then chal-
lenged produced higher levels of IFN- than mice immunized
with CEL-1000–HEP17 and then challenged (Fig. 1), and
IFN- is absolutely required for protection against sporozoite
challenge (3, 4, 22, 23). (ii) Mice that received CEL-1000 alone
developed only a Th1 response, as shown by the high levels of
IFN- produced in their sera with no detectable antibodies to
CEL-1000, while mice that received CEL-1000–HEP17 devel-
oped HEP17-specific antibodies and IFN-, indicative of both
Th2 and Th1 responses. The Th2 portion of the response may
downregulate the Th1 response (IFN- production), thereby
diminishing protection.
P. yoelii sporozoites are highly infectious. Injection of 100
sporozoites intravenously consistently infected 100% of A/J
mice within 14 days. The findings that two injections of as low
as 1.25 g of CEL-1000 in TiterMax adjuvant could protect
60% of these mice against challenge with 100 P. yoelii sporo-
zoites and that two injections of only 5 g of CEL-1000 could
protect 100% of the mice against challenge with up to 5,000
sporozoites clearly demonstrate that CEL-1000 has a potent
prophylactic ability in the P. yoelii model of malaria. CEL-1000
at the same doses was also able to confer some degree of
protection against a second species of organisms causing ma-
laria, the more virulent species P. berghei (lethal strain
ANKA), although the protection conferred was not as strong
as that conferred against P yoelii (a nonlethal strain). This
regimen of treatment (two doses of 5 g of the CEL-1000
peptide at 3-week intervals) may not be adequate, and it is
possible that a higher dose of CEL-1000 may be required to
induce complete protection against P. berghei, a highly virulent
species causing malaria. It should be noted that in our studies
parasitemia and not death was used as the end point of the
assay.
Evaluation of the kinetics and the maintenance of protection
indicated that protection could be achieved as early as 1 week
after the administration of one or two doses of CEL-1000
(40% of the mice were protected after they received a single
dose and 90% were protected after they received two doses).
The levels of protection increased with time and reached a
peak when the mice were challenged 4 weeks after CEL-1000
treatment (90% were protected after they received a single
dose and 100% were protected after they received two doses).
The two-dose regimen resulted in a higher level of protection
than the single-dose regimen at both early (1 week) and late (4
weeks) times of challenge. The protected mice that received
TABLE 3. Protection against P. yoelii sporozoite challenge in different mouse strains following treatment
with CEL-1000 in TiterMax adjuvanta
Expt no. and mouse
strain Treatment or group
No. of mice
protected/no. tested % Protection P value
b
Expt 1
A/J (H-2a) CEL-1000, TiterMax adjuvant 10/10 100 0.0000077
TiterMax adjuvant (control) 0/10 0
Infectivity control 0/10 0
BALB/c (H-2d) CEL-1000, TiterMax adjuvant 1/10 10
TiterMax adjuvant (control) 1/10 10
Infectivity control 0/10 0
Expt 2
A/J (H-2a) CEL-1000, TiterMax adjuvant 8/10 80 0.0002607
TiterMax adjuvant (control) 0/10 0
Infectivity control 0/10 0
BALB/c (H-2d) CEL-1000, TiterMax adjuvant 0/10 0
TiterMax adjuvant (control) 1/10 10
Infectivity control 0/10 0
CAF1 (F1 hybrid) CEL-1000, TiterMax adjuvant 0/10 0
TiterMax adjuvant (control) 1/10 10
Infectivity control 0/10 0
C3H/HeJ (H-2k) CEL-1000, TiterMax adjuvant 4/10 40 0.0327271
TiterMax adjuvant (control) 0/9 0
Infectivity control 0/10 0
a Mice were injected twice at 3-week intervals with 25 g of CEL-1000 in TiterMax adjuvant and were challenged with 100 P. yoeliii sporozoites 2 weeks after the
second injection. Mice that received TiterMax adjuvant alone and malaria-naı¨ve mice served as negative controls. Parasitemia was determined as described in Materials
and Methods. Protection was defined as negative blood smear results through 14 days postchallenge.
b A P value 0.05 (chi-square test) compared to the results for the TiterMax adjuvant-treated control was considered significant.
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two doses of CEL-1000 were rechallenged with 100 sporozoites
4 months later, and 80% of these mice did not become in-
fected, suggesting that the protection induced is long lasting.
Treatment with CEL-1000 before challenge with a dose of
sporozoites more massive (n 50,000) than that normally used
to infect all animals (100 sporozoites) significantly reduced the
liver stage parasite burden (400-fold [P 0.01]) compared to
that in the TiterMax adjuvant-treated controls. CEL-1000 con-
ferred no protection against blood stage parasite challenge.
Together, these results establish that the protection induced by
CEL-1000 is targeted at the liver stage and not at the blood
stage.
The finding that CEL-1000 protected A/J mice in the ab-
sence of malaria antigens is very much surprising to us. It is not
clear why this peptide is protective. To our knowledge, there is
no report indicating that CEL-1000 contains an amino acid
sequence homologous to amino acid sequences of P. yoelii and
HSV antigens. This is the first report indicating that a peptide
derived from the  chain of human MHC-II effectively offers
protection against malaria. We therefore decided to further
evaluate the possible mechanisms associated with this protec-
tion by performing a depletion study.
Analyses of cell populations in CEL-1000-treated and pro-
tected mice demonstrated elevations in the frequencies of he-
patic CD4 IFN- T cells but not CD8 T cells or NK cells.
In addition, elevated levels of splenic CD4 IFN- cells but
not CD8 T cells or NK cells were also observed, suggesting
that other cell types may contribute in part to the production
of IFN- responsible for this protection. In vivo depletion of
cell subsets and cytokines from CEL-1000-treated mice just
prior to challenge with P. yoelii sporozoites established that the
protection delivered by CEL-1000 was totally dependent on
IFN-  and was partially dependent on CD4 T cells but was
not dependent on CD8 T cells, NK cells, or IL-12. The exact
mechanism of CEL-1000-induced protection is not completely
understood at present and may be due in part to the produc-
tion of nitric oxide as a consequence of the action of IFN-. In
vitro and in vivo data from other studies indicate that the
IFN- produced by malaria parasite-specific CD8 T cells
stimulated Plasmodium-infected hepatocytes to produce NO
to eliminate the liver stage parasites (11, 12).
Treatment of A/J (H-2a) or C3H (H-2k) mice with CEL-1000
prior to challenge with infectious P. yoelii sporozoites, in the
absence of malaria antigen, solidly protected the mice against
parasite challenge. Interestingly, CEL-1000 was not protective
in BALB/c (H-2d) or CAF1 (A/J  BALB/c F1 hybrid) mice,
indicating genetic differences in the effects of CEL-1000. Oth-
ers have shown that BALB/c mice are more susceptible to
infections with parasites, such as Leishmania major, since they
are prone to have Th2-type immune responses (6, 7, 8, 13, 14,
16), and this offers an explanation for the lack of protection in
CEL-1000-treated BALB/c mice upon challenge with P. yoelii
sporozoites.
It appears that the mechanism associated with the protec-
tion induced by CEL-1000 in this study is similar to that in-
duced by two malaria parasite peptides, PyHEP17 and PySSP2,
which also depend on IFN- and CD4 T cells (3, 23), but is
different from that induced by P. yoelii-irradiated sporozoites
or circumsporozoite protein DNA vaccine, which is dependent
on CD8 T cell or CD8 T cells plus NK cells for the produc-
tion of the IFN-, IL-12, and nitric oxide that are responsible
for this protection (4, 21, 22, 24). In the HSV model, treatment
of mice with CEL-1000 confers protection against HSV-1 chal-
lenge, and this protection appears to be initiated by IL-12, as
indicated by the rapid and prolonged (5 days) appearance of
IL-12 in the sera after CEL-1000 treatment, and on the basis of
MAb treatment involves CD4 cells and IFN- but not CD8
cells (N. Goel, unpublished observations). IL-12 is a strong
inducer of IFN- production by CD4 and NK cells. However,
IL-12 production could be involved in CEL-1000-mediated
protection in the inductive phase and not at the effector or
challenge phase, or it may not be involved at all in CEL-1000-
mediated protection, which explains the ineffectiveness of anti-
IL-12 and anti-NK cell antibodies at the challenge phase in the
murine model of P. yoelii malaria. The exact mechanism of
CEL-1000-induced protection is unknown. The restriction of
protection to mouse strains with certain genetic backgrounds is
probably due to differences at the MHC-II loci, which are
identical in A/J and C3H/HeJ mice (I-Ak, I-Ek), which were
protected. These loci are totally different from those in the
nonprotected BALB/c strain (I-Ad, I-Ed). The protection in-
duced by CEL-1000 could also be due to nonspecific stimula-
tion of cytokine production. A/J mice have the ability to pro-
duce IL-12 (1, 10), while this ability is defective in BALB/c
mice (6, 7, 8, 16); and IL-12 is a potent activator of IFN-
production (Th1 response). However, these mechanisms are
only speculations. Detailed studies to determine the exact
mechanisms responsible for CEL-1000-induced protection need
to be further elucidated.
In summary, we have demonstrated that treatment with the
CEL-1000 peptide prior to challenge with sporozoites from
P. yoelii protects A/J and C3H/HeJ mice against parasite chal-
lenge. This protection is totally dependent on IFN-, is par-
tially dependent on CD4 T cells, but is not dependent on
IL-12, CD8 T cells, or NK cells. We have also demonstrated
that CEL-1000 is a very potent prophylactic agent, with only
two injections of 5 g each conferring complete protection
against challenge with up to 5,000 sporozoites (500 times the
minimum infectivity dose). Moreover, CEL-1000 has also been
shown to induce protection against HSV-1 challenge (N. Goel,
unpublished), and this protection is also dependent on CD4
T cells and IFN-. Together, these results demonstrate that
CEL-1000 has a potential prophylactic capability against ma-
laria and HSV, with the data for HSV also suggesting that it
has therapeutic potential. Further evaluation of the capacity of
CEL-1000 to protect against other malaria parasite species and
other diseases whose protection is mediated by Th1-type im-
munity is warranted.
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